Study to Evaluate the Safety and Effectiveness of MynxGrip Vascular Closure Device (PANDA)

A Multicenter, Open Label, Prospective, Randomized Study of the MynxGrip Vascular Closure Device in Subjects With Diagnostic or Interventional Endovascular Procedures (PANDA Study)

To evaluate the safety and effectiveness of MynxGrip, in hemostasis of common femoral artery puncture site, compared with manual compression hemostasis in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.

Study Overview

• Status: Completed
• Conditions: Endovascular
• Intervention / Treatment: Device: MynxGrip; Other: Manual compression

Detailed Description

Effectiveness: to superiority to the control group in time to hemostasis. Comparison of time to ambulation, procedure success rate, length of stay in hospital, device success rate.

Safety-Major/Minor complication rate, adverse events, SAEs as compared to control.

• Study Type: Interventional
• Enrollment (Actual): 306
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100068
    • Beijing Tiantan Hospital Capitol Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients ≥ 18 years of age;
2. Patients who are able and willing to sign the informed consent form;
3. Patients who agree to follow all study visits and procedures;
4. Patients who plan to receive the diagnostic or interventional endovascular procedures via percutaneous common femoral artery puncture;
5. Patients who are able to walk, as judged by the investigators.

Exclusion Criteria:

1. Patients are proved to have clinically significant peripheral vascular disease according to any of the following situations:

   1. Patients showing severe claudication after walking less than 200 meters,
   2. No palpable pulse on the patients' affected limbs,
   3. Patients having received surgical procedures involving the ipsilateral common femoral artery
   4. Patients having received percutaneous transluminal angioplasty (PTA), stent placement, or vascular graft in the ipsilateral common femoral artery;
2. Patients with morbid obesity (BMI > 40 kg/m2);
3. Patients with a myocardial infarction (MI) with acute elevated ST segment ≤24 hours prior to procedure;
4. Patients with the prior procedure in the ipsilateral common femoral artery ≤30 days;
5. Patients having received ipsilateral vascular closure device;
6. Patients with bleeding disorders such as thrombocytopenia (platelet count < 100,000/ mm3), hemophilia, von Willebrand disease or severe anemia (Hgb < 10 g/dL, Hct < 30%);
7. Patients with documented INR > 1.5 or patients currently receiving glycoprotein IIb/IIIa platelet inhibitors;
8. Patients with symptoms of local infection or inflammation in the groin;
9. Patients who are participating in any other clinical studies on drugs or medical devices at the same time;
10. Patients who are pregnant or in lactation;
11. Patients with known allergy to contrast medium;
12. Patients with known allergy to polyethylene glycol;
13. Patients with treated but still uncontrolled hypertension (systolic pressure>180 mmHg or diastolic pressure>110 mmHg);
14. Patients with known autoimmune diseases;
15. Patients who are receiving long-term corticosteroid therapy;
16. Patients with expected life of less than 30 days;
17. Patients with unilateral or bilateral lower-extremity amputation;
18. Patients who can't walk 6 meters (20 steps) without a support for any reason;
19. Patients requiring prolonged length of stay [For example, the patient will receive the coronary artery bypass grafting (CABG) or the patient plans to receive the CABG ≤30 days after the surgery];
20. Patients with mental disorders and cognitive impairment;
21. Patients have participated into this study before; Intra-operative exclusion criteria;
22. Patients with treated but still uncontrolled hypertension (systolic pressure>180 mmHg or diastolic pressure>110 mmHg);
23. Patients implanted with a balloon pump inside the aorta;
24. Patients whose common femoral artery is too thin (<5 mm in diameter);
25. Patients with obviously fibrotic, calcified, or >50% stenotic femoral artery;
26. Patients having received puncture at other artery than the common femoral artery;
27. Patients having received antegrade puncture;
28. Patients having received arterial puncture at a number of different sites or who are suspected to have received posterior femoral arterial wall puncture;
29. Patients implanted with ipsilateral venous sheath;
30. Surgical findings or complications which the investigators consider may interfere with the patients' participation into the study (For example, the sheath deployment is difficult due to the scar, tortuous vessels, or use of the sheath with the other sizes than 5 Fr, 6 Fr or 7 Fr, or the sheath with the total length of >15.7 cm);
31. Patients with preexisting hematoma, intraluminal thrombus, pseudoaneurysm, AV Fistula or any type of dissection;
32. Patients requiring prolonged length of stay [For example, the patient will receive the coronary artery bypass grafting (CABG) or the patient plans to receive the CABG ≤30 days after the surgery];
33. Patients who are included in another drug or medical device study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MynxGrip; MynxGrip, a vascular closure device indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.	Device: MynxGrip; Vascular Closure
Active Comparator: Manual compression; Manual compression hemostasis	Other: Manual compression; Manual compression is a commonly used method to achieve hemostasis of femoral artery

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Effectiveness Endpoint: Time to Hemostasis	The time to hemostasis is defined as the time from the sheath removal to the time to achieving hemostasis for the subject. The "hemostasis" here refers to that at the puncture site, there is no pulsating bleeding, nor expansionary/progressive hematoma.	Post procedure (time from the sheath removal to the time to achieving hemostasis)
Primary Safety Endpoint: Major Complication Rate	Defined as major complications during procedure, at discharge, and 30 days post procedure: vascular injury or vascular repair required; Permanent access site-related nerve injury; Access site-related nerve injury requiring a surgery; Access site-related bleeding requiring transfusion; New ipsilateral lower extremity ischemia discovered, which requires invasive/noninvasive intervention; Local access site-related infection combined with other indicators, which requires intervention; Classic signs/symptoms occurred in a short time after receiving the specified hemostasis procedures and generalized infection with positive blood culture, sepsis, which requiring intervention; Inflammatory reaction, including the local reaction and discharge of pus, which requires intervention	Through 30 days post procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary Effectiveness Endpoint: Time to Ambulation	Defined as the time (in minutes) from sheath removal to when the patient can walk about at least 6 meters (or 20 steps). Compare whether there are differences in the time to ambulation (for patients receiving a diagnostic procedure) between the two groups.	Post procedure
Secondary Effectiveness Endpoint: Length of Hospital Stay	Defined as the time (in minutes) from sheath removal to patient discharge (for patients receiving a diagnostic procedure). Compare whether there are differences in the length of stay (for patients receiving a diagnostic procedure) between the two groups.	Index procedure through discharge
Secondary Effectiveness Endpoint: Procedure Success Rate	Defined as successfully achieving hemostasis using the investigational medical device or control methods (including but are not limited to the assigned therapeutic method and other supplementary means) with absence of major complications. Compare whether there are differences in the procedure success rate (for patients receiving a diagnostic procedure) between the two groups.	Index procedure
Secondary Effectiveness Endpoint: Device Success Rate	Defined as the device being successfully removed in accordance with the standard operating procedure	Intraoperatively
Secondary Safety Endpoint: Minor Complication Rate	Compare whether there are differences in rates of minor complications between the two groups	Through 30 days post procedure

Collaborators and Investigators

• Sponsor: Cordis US Corp.
• Collaborators: Kun Tuo
• Investigators: Principal Investigator: Prof. Miao Zhongrong, MD, Beijing Tian Tan Hospital, Capital Medical University

Study record dates

Study Major Dates

• Study Start (Actual): April 24, 2019
• Primary Completion (Actual): October 22, 2020
• Study Completion (Actual): October 22, 2020

Study Registration Dates

• First Submitted: April 17, 2019
• First Submitted That Met QC Criteria: April 18, 2019
• First Posted (Actual): April 22, 2019

Study Record Updates

• Last Update Posted (Actual): July 29, 2026
• Last Update Submitted That Met QC Criteria: July 1, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Vascular closure
• Other Study ID Numbers: P17-0005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes